Company: LRHC
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112656
Chunk: 47

Company: La Rosa Holdings Corp.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 47
---
 has the right to issue and sell to the Investor up to $150 million (subsequently
amended to $1 billion on September 18, 2025) in newly issued shares of the Company’s common stock (the “Commitment Amount”).
The term of the facility provided under the EPFA expires on the earlier to occur of (i) the first day of the next month following the
36-month anniversary of the first trading date after the Agreement Date and (ii) the date on which the Investor shall have made payment
of advances pursuant to the EPFA for common shares equal to the Commitment Amount; provided that the Company may terminate the EPFA effective
upon five trading days’ prior written notice to the Investor (provided that there are no outstanding advance notices the common
shares under which have yet to be issued).

On
September 18, 2025, the Company and the Investor entered into the Amended and Restated Equity Purchase Facility Agreement in order to
increase the Commitment Amount to $1 billion as described above. All other terms and provisions were substantially the same as the initial
EPFA.

26

La
Rosa Holdings Corp. and Subsidiaries
Notes to the Unaudited Condensed Consolidated Financial Statements

Under
the terms of the EPFA, the Company has the right (but not the obligation) to request that the Investor purchase shares of the Company’s
Common Stock, subject to certain conditions and limitations (an “Advance”). The purchase price of the shares to be sold under
an Advance is 100% of the Market Price, which is generally defined as the lower of (i) the lowest price of the Common Stock traded during
the relevant pricing period and (ii) the lowest daily (or hourly) VWAP during the relevant pricing period. In the event the bid price
of the common stock is at or below $0.10 per share, the Investor will have the right to consent to any Advance. Any purchase under an
Advance would be subject to certain limitations, including that the Investor shall not purchase any shares of Common Stock that would
result in the Investor beneficially owning more than 4.99% of the outstanding common shares or voting power of the Company (the Investor
can request to increase this limit to 9.99%). Additionally, any purchase under an Advance would also be subject to a 19.99% limit based
on the outstanding shares of common stock at the issuance date, prior to the receipt of shareholder